Every now and then,New Scientisthelps a carefully selected commercial partner speak to our audience. Their support helps us produce the high quality journalism we bring you every week. We hope you find today's message relevant and useful.

As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.

Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency.